Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma
Authors
Keywords
-
Journal
PEDIATRIC BLOOD & CANCER
Volume 62, Issue 10, Pages 1768-1774
Publisher
Wiley
Online
2015-05-16
DOI
10.1002/pbc.25579
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BRAFMutation andCDKN2ADeletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma
- (2015) Matthew Mistry et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas
- (2015) Catherine Louise Penman et al. Frontiers in Oncology
- FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3-FOXO1 Fusion Gene
- (2014) M. Singh et al. CLINICAL CANCER RESEARCH
- Radiologic Differences between Bone Marrow Stromal and Hematopoietic Progenitor Cell Lines from Fanconi Anemia (Fancd2–/–) Mice
- (2014) Hebist Berhane et al. RADIATION RESEARCH
- Transforming Growth Factor Alpha is a Critical Mediator of Radiation Lung Injury
- (2014) Eun Joo Chung et al. RADIATION RESEARCH
- Dysembryoplastic Neuroepithelial Tumors Share with Pleomorphic Xanthoastrocytomas and Gangliogliomas BRAFV600EMutation and Expression
- (2013) Céline Chappé et al. BRAIN PATHOLOGY
- Regulation of FANCD2 by the mTOR Pathway Contributes to the Resistance of Cancer Cells to DNA Double-Strand Breaks
- (2013) C. Shen et al. CANCER RESEARCH
- Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma
- (2013) H. K. Bid et al. CLINICAL CANCER RESEARCH
- Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis
- (2013) F. Guo et al. HAEMATOLOGICA
- Using NanoDot dosimetry to study the RS 2000 X-ray Biological Irradiator
- (2013) Lanchun Lu et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells
- (2013) F Guo et al. LEUKEMIA
- TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
- (2013) R. B. Corcoran et al. Science Translational Medicine
- Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
- (2012) Joann L. Ater et al. JOURNAL OF CLINICAL ONCOLOGY
- The application of radiation therapy to the pediatric preclinical testing program (PPTP): Results of a pilot study in rhabdomyosarcoma
- (2012) Rita Kaplon et al. PEDIATRIC BLOOD & CANCER
- Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
- (2011) Genevieve Schindler et al. ACTA NEUROPATHOLOGICA
- Targeted Therapy for BRAFV600E Malignant Astrocytoma
- (2011) T. P. Nicolaides et al. CLINICAL CANCER RESEARCH
- Primary Neurosurgery for Pediatric Low-Grade Gliomas: A Prospective Multi-Institutional Study From the Children's Oncology Group
- (2011) Jeffrey H. Wisoff et al. NEUROSURGERY
- BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
- (2011) Dora Dias-Santagata et al. PLoS One
- Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas
- (2010) J. D. Schiffman et al. CANCER RESEARCH
- Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome
- (2010) Yoon-Jae Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Subtypes of medulloblastoma have distinct developmental origins
- (2010) Paul Gibson et al. NATURE
- Cross-species genomics matches driver mutations and cell compartments to model ependymoma
- (2010) Robert A. Johnson et al. NATURE
- Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program
- (2010) E. Anders Kolb et al. PEDIATRIC BLOOD & CANCER
- The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma
- (2009) R. T. Kurmasheva et al. CANCER RESEARCH
- In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase
- (2009) E. J. Chung et al. CLINICAL CANCER RESEARCH
- The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts
- (2009) A. M. Shannon et al. CLINICAL CANCER RESEARCH
- Clinical Radiation Sensitivity With DNA Repair Disorders: An Overview
- (2009) Julianne M. Pollard et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase II Trial of Conformal Radiation Therapy for Pediatric Low-Grade Glioma
- (2009) Thomas E. Merchant et al. JOURNAL OF CLINICAL ONCOLOGY
- Tandem Duplication Producing a Novel OncogenicBRAFFusion Gene Defines the Majority of Pilocytic Astrocytomas
- (2008) David T.W. Jones et al. CANCER RESEARCH
- Frequent Gains at Chromosome 7q34 Involving BRAF in Pilocytic Astrocytoma
- (2008) Eli E. Bar et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo
- (2008) H. Hamed et al. MOLECULAR CANCER THERAPEUTICS
- Outcome analysis of childhood low-grade astrocytomas
- (2008) Paul G. Fisher et al. PEDIATRIC BLOOD & CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started